Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 4
2015 1
2016 1
2017 2
2018 1
2019 2
2020 5
2021 10
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, Müller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Crews KR, et al. Clin Pharmacol Ther. 2021 Oct;110(4):888-896. doi: 10.1002/cpt.2149. Epub 2021 Feb 9. Clin Pharmacol Ther. 2021. PMID: 33387367 Review.
Other genes that have been studied for their association with opioid clinical effect or adverse events include OPRM1 (mu receptor) and COMT (catechol-O-methyltransferase). This guideline updates and expands the 2014 Clinical Pharmacogenetics Implementation Consortiu …
Other genes that have been studied for their association with opioid clinical effect or adverse events include OPRM1 (mu receptor) and COMT …
Status Toward the Implementation of Precision Dosing in Children.
Barrett JS, Barrett RF, Vinks AA. Barrett JS, et al. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S36-S51. doi: 10.1002/jcph.1830. J Clin Pharmacol. 2021. PMID: 34185896 Review.
Precision dosing is progressing beyond the conceptual and proof-of-concept stages toward implementation. As the availability of dosing algorithms, tools, and platforms increases, so do the investment in technology services and actual implementation of clinical servi …
Precision dosing is progressing beyond the conceptual and proof-of-concept stages toward implementation. As the availability of dosin …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Lima JJ, et al. Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423. doi: 10.1002/cpt.2015. Epub 2020 Sep 20. Clin Pharmacol Ther. 2021. PMID: 32770672 Free PMC article.
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes DJAR, Oellerich M, Picard N, Salzmann L, Tönshoff B, van Schaik RHN, Vethe NT, Vinks AA, Wallemacq P, Åsberg A, Langman LJ. Bergan S, et al. Ther Drug Monit. 2021 Apr 1;43(2):150-200. doi: 10.1097/FTD.0000000000000871. Ther Drug Monit. 2021. PMID: 33711005 Review.
Topics included are the criteria for analytics, methods to estimate exposure including pharmacometrics, the potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention. ...
Topics included are the criteria for analytics, methods to estimate exposure including pharmacometrics, the potential influence of pharma
Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology.
Ramsey LB, Namerow LB, Bishop JR, Hicks JK, Bousman C, Croarkin PE, Mathews CA, Van Driest SL, Strawn JR. Ramsey LB, et al. J Am Acad Child Adolesc Psychiatry. 2021 Jun;60(6):660-664. doi: 10.1016/j.jaac.2020.08.006. Epub 2020 Aug 26. J Am Acad Child Adolesc Psychiatry. 2021. PMID: 32860906 Free PMC article.
AACAP's recent policy statement on Clinical Use of Pharmacogenetic Tests in Prescribing Psychotropic Medications for Children and Adolescents(1) recommends that "clinicians avoid using pharmacogenetic testing to select psychotropic medications in ch
AACAP's recent policy statement on Clinical Use of Pharmacogenetic Tests in Prescribing Psychotropic Medications for Childr
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH; IGNITE Network Pharmacogenetics Working Group. Duarte JD, et al. Genet Med. 2021 Dec;23(12):2335-2341. doi: 10.1038/s41436-021-01269-9. Epub 2021 Jul 19. Genet Med. 2021. PMID: 34282303 Free PMC article.
RESULTS: We found that while pre-emptive PGx testing models varied across sites, institutions shared several commonalities, including methods to identify patients eligible for testing, involvement of a precision medicine clinical team in program leadership, and the implementat
RESULTS: We found that while pre-emptive PGx testing models varied across sites, institutions shared several commonalities, including method …
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. Cooper-DeHoff RM, et al. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. Clin Pharmacol Ther. 2022. PMID: 35152405
Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. …
Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin th …
Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care.
Mizuno T, Dong M, Taylor ZL, Ramsey LB, Vinks AA. Mizuno T, et al. Br J Clin Pharmacol. 2022 Feb;88(4):1418-1426. doi: 10.1111/bcp.14426. Epub 2020 Jul 8. Br J Clin Pharmacol. 2022. PMID: 32529759 Review.
Such an approach was pioneered in the late 1970s, but its broad clinical acceptance and implementation have been hampered by the lack of widespread computer technology, including user-friendly software tools. ...Advanced pharmacometrics research is now more appliable and …
Such an approach was pioneered in the late 1970s, but its broad clinical acceptance and implementation have been hampered by the lack …
26 results